FDA opens fast-track review process for national health priorities

Published



The Food and Drug Administration announced the launch of a new program to fast-track agency approvals for drug manufacturers working on products that could cure chronic disease, prepare for a pandemic, or address other national public health priorities.

FDA Commissioner Dr. Marty Makary announced on Tuesday that, beginning this year, the Commissioner’s National Priority Voucher, or CNPV, program would reduce approval times from the current 10 to 12-month wait to only one or two months following a final drug application submission. 

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.